- |||||||||| ibuprofen / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Observational data, Journal, Surgery: Prolonged opioid use after single-level lumbar spinal fusion surgery in a Belgian population: a multicentric observational study. (Pubmed Central) - Sep 21, 2024
The study underscores the importance of tailored pain management strategies, particularly given the rising prevalence of spinal fusion surgeries. The association between pre-operative low back pain, post-operative improvement in functionality (ODI), and prolonged opioid use emphasizes the need for judicious opioid prescribing practices and highlights the role of functional outcomes in treatment goals.
- |||||||||| oxycodone/naloxone ER / Generic mfg.
Review, Journal: Managing Severe Cancer Pain with Oxycodone/Naloxone Treatment: A Literature Review Update. (Pubmed Central) - May 25, 2024
Through a comprehensive search of databases, studies focusing on the efficacy, safety, and patient experience of oxycodone/naloxone's prolonged release in severe cancer pain management were identified...Overall, the evidence suggests that oxycodone/naloxone combination therapy offers a valuable option for effectively managing severe cancer pain while minimizing opioid-induced constipation, thereby improving patients' quality of life. However, further research is needed to optimize dosing regimens, evaluate long-term safety, and assess patient outcomes in diverse cancer populations.
- |||||||||| pregabalin / Generic mfg.
Trial completion date, Trial primary completion date: Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia (clinicaltrials.gov) - Jul 20, 2023
P2/3, N=150, Enrolling by invitation,
However, further research is needed to optimize dosing regimens, evaluate long-term safety, and assess patient outcomes in diverse cancer populations. Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
- |||||||||| pregabalin / Generic mfg.
Trial completion date, Trial primary completion date: Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia (clinicaltrials.gov) - Feb 1, 2023
P2/3, N=150, Enrolling by invitation,
Trial completion date: May 2023 --> May 2024 | Trial primary completion date: Apr 2023 --> Apr 2024 Trial completion date: Jan 2023 --> May 2023 | Trial primary completion date: Jan 2023 --> Apr 2023
- |||||||||| pregabalin / Generic mfg.
Trial completion date, Trial primary completion date: Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia (clinicaltrials.gov) - Dec 30, 2022
P2/3, N=150, Enrolling by invitation,
Trial completion date: Jan 2023 --> May 2023 | Trial primary completion date: Jan 2023 --> Apr 2023 Trial completion date: Jul 2023 --> Jan 2023 | Trial primary completion date: Jun 2023 --> Jan 2023
- |||||||||| oxycodone controlled release / Generic mfg.
Retrospective data, Journal: Oxycodone-Naloxone Combination Hinders Opioid Consumption in Osteoarthritic Chronic Low Back Pain: A Retrospective Study with Two Years of Follow-Up. (Pubmed Central) - Oct 28, 2022
In 2019, 53 patients suffering from CLBP were treated with either Oxycodone and Naloxone Prolonged Release (27 patients, OXN patients) or Oxycodone Controlled Release (26 patients, OXY patients)...From our results, we can affirm that a long-term opioid treatment with oxycodone-naloxone combination, when compared with oxycodone only, may significantly hinder the development of opioid tolerance. We were also able to confirm, in our cohort, the well known positive effect of naloxone in terms of opioid-induced bowel dysfunction incidence reduction.
- |||||||||| Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma, OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
Trial completion date, Trial primary completion date, Monotherapy, Metastases: NanaBis (clinicaltrials.gov) - Apr 12, 2022
P3, N=360, Not yet recruiting,
This was due to them having Orthopaedic surgery not related to this study. Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Aug 2023 --> Feb 2024
- |||||||||| oxycodone/naloxone ER / Generic mfg.
Trial completion, Enrollment change, Trial completion date: Targin (clinicaltrials.gov) - Dec 10, 2021
P4, N=1, Completed,
Presence of hepatic impairment should thus be considered when medication-related outcomes with oxycodone-naloxone combination are not as expected, even if liver function test results are normal. Recruiting --> Completed | N=20 --> 1 | Trial completion date: Dec 2022 --> Nov 2021
- |||||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Journal, Adverse events: Pharmacovigilance in Hospice/Palliative Care: De-Prescribing Combination Controlled Release Oxycodone-Naloxone. (Pubmed Central) - Jun 22, 2021
This meta-analysis confirms existing evidence on OXN’s c with moderate-severe CP. The last median oral morphine equivalent oxycodone dose before the switch was 45 mg (range 7.5-240 mg) with 76 switched to an alternative long-acting opioid (initial median oral morphine equivalent dose being 45 mg [range 5-210 mg])...This preliminary work suggests that despite theoretical concerns regarding the effect of the naloxone on opioid doses, most people were switched safely to very similar opioid doses with attendant improvements in pain control.
- |||||||||| duloxetine / Generic mfg.
Journal: Current status of pain management in Parkinson's disease. (Pubmed Central) - Jun 8, 2021
Duloxetine provided benefit in an open-label trial. Oxycodone-naloxone PR did not have a significant improvement in pain, but per-protocol analysis showed a reduction in pain when adherence was strong...Safinamide significantly improved the "bodily discomfort" domain in the PDQ-39 questionnaire...No abstract available
- |||||||||| oxycodone/naloxone ER / Generic mfg.
Trial completion date, Trial primary completion date: Targin (clinicaltrials.gov) - Apr 22, 2021
P4, N=20, Recruiting,
Oxycodone-naloxone PR did not have a significant improvement in pain, but per-protocol analysis showed a reduction in pain when adherence was strong...Safinamide significantly improved the "bodily discomfort" domain in the PDQ-39 questionnaire...No abstract available Trial completion date: Mar 2022 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Dec 2021
- |||||||||| Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma, OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
New P3 trial, Monotherapy, Metastases: NanaBis (clinicaltrials.gov) - Mar 21, 2021
P3, N=360, Not yet recruiting,
- |||||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Trial completion: Efficacy and Safety of Oxycodone/Naloxone (Targin (clinicaltrials.gov) - Jan 25, 2021
P4, N=123, Completed,
Our findings highlight the need for updated guidelines around risk management for opioid treatment in patients with cancer. Active, not recruiting --> Completed
- |||||||||| Review, Journal: Chronic Pain Treatment Strategies in Parkinson's Disease. (Pubmed Central) - Nov 23, 2020
Anticonvulsants such as gabapentin, pregabalin, lamotrigine, carbamazepine and tricyclic antidepressants (TCAs) can be trialed when attempting to manage chronic pain in PD...A treatment plan can be devised that may include dopaminergic agents, acetaminophen, NSAIDs, opioids, antidepressants, physical therapies, DBS and other options discussed in this review. A thorough assessment of patient history and physical examination should be made in patients with PD so chronic pain may be managed effectively.
- |||||||||| Duragesic (fentanyl) / J&J, Targin (oxycodone/naloxone ER) / Shionogi, Purdue, Mundipharma
[VIRTUAL] Prolonged release (PR) oxycodone/naloxone (OXN) for cancer pain (CP) & its impact on bowel function, safety & quality of life (QoL): Systematic review (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_946;
Systematic review of literature from PubMed and EMBASE that evaluated analgesia, bowel function, adverse events (AE) and QoL after OXN PR or oral oxycodone (OXY)/morphine/tapentadol PR, or transdermal fentanyl, in adults with moderate-severe CP...Although limited, this meta-analysis confirms existing evidence on OXN’s efficacy and tolerability in patients with moderate-severe CP and highlights that few data on OXN in CP is available. Mundipharma Singapore Holding Pte Ltd.
- |||||||||| Duragesic (fentanyl) / J&J, Targin (oxycodone/naloxone ER) / Shionogi, Purdue, Mundipharma
[VIRTUAL] Prolonged release (PR) oxycodone/naloxone (OXN) for cancer pain (CP) & its impact on bowel function, safety & quality of life (QoL): Systematic review (On-Demand e-Poster Display) - Oct 8, 2020 - Abstract #ESMOAsia2020ESMO_Asia_580;
Systematic review of literature from PubMed and EMBASE that evaluated analgesia, bowel function, adverse events (AE) and QoL after OXN PR or oral oxycodone (OXY)/morphine/tapentadol PR, or transdermal fentanyl, in adults with moderate-severe CP...Although limited, this meta-analysis confirms existing evidence on OXN’s efficacy and tolerability in patients with moderate-severe CP and highlights that few data on OXN in CP is available. Mundipharma Singapore Holding Pte Ltd.
- |||||||||| Targin (oxycodone/naloxone ER) / Shionogi, Purdue, Mundipharma
Preclinical, Journal: Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the Restless Legs Syndrome. (Pubmed Central) - Sep 13, 2020
It is also the first study showing that opioid receptors are involved in the production of motor restlessness with a circadian predominance. Our findings support the role of endogenous opioids in the pathogenesis of RLS, and the triple KO mice can be used to understand the relationship between iron deficiency, anemia, dopaminergic dysfunction, and RLS.
- |||||||||| Xadago (safinamide) / Zambon, US WorldMeds, Meiji Seika, Valeo Pharma, Eisai, duloxetine delayed release / Generic mfg., Targin (oxycodone/naloxone ER) / Shionogi, Purdue, Mundipharma
Journal: Pain in Parkinson's disease: new concepts in pathogenesis and treatment. (Pubmed Central) - Apr 22, 2020
The management of Parkinson's disease-related pain implicates maintenance of stable levels of dopaminergic drugs. Nondopaminergic pharmacological therapies (prolonged-release oxycodone/naloxone, duloxetine, BTX) and nonpharmacological interventions (DBS, physiotherapie) may also be beneficial in treatment of Parkinson's disease pain.
- |||||||||| oxycodone controlled release / Generic mfg., oxycodone/naloxone ER / Generic mfg.
Enrollment closed, Trial completion date: Efficacy and Safety of Oxycodone/Naloxone (Targin (clinicaltrials.gov) - Apr 19, 2020
P4, N=123, Active, not recruiting,
Nondopaminergic pharmacological therapies (prolonged-release oxycodone/naloxone, duloxetine, BTX) and nonpharmacological interventions (DBS, physiotherapie) may also be beneficial in treatment of Parkinson's disease pain. Recruiting --> Active, not recruiting | Trial completion date: Apr 2020 --> Oct 2020
- |||||||||| Targin (oxycodone/naloxone ER) / Shionogi, Purdue, Mundipharma
Journal: A new species of the genus Tatargina (Lepidoptera, Erebidae, Arctiinae) from Cambodia. (Pubmed Central) - Apr 9, 2020
A new species of the Tatargina Butler, T. erythromelaena Bayarsaikhan Bae, n. sp., is described from Cambodia, with a recorded species, T. picta (Walker). Illustrations of adults and male genitalia of Cambodia and Thailand species are presented.
- |||||||||| Targin (oxycodone/naloxone ER) / Shionogi, Purdue, Mundipharma
The contribution of an emergency department to the opioid crisis. () - Sep 10, 2019 - Abstract #EUSEM2019EUSEM_1003;
The inappropriate prescribing of these medications is increasing, and we are on a trajectory to cause significant community harm. Interventions in prescribing behaviour are required if to prevent Australian EDs from contributing to the potential development of a public health crisis.
- |||||||||| oxycodone/naloxone ER / Generic mfg.
Enrollment open, Phase classification, Trial completion date, Trial primary completion date: Targin (clinicaltrials.gov) - Sep 9, 2019
P4, N=20, Recruiting,
Interventions in prescribing behaviour are required if to prevent Australian EDs from contributing to the potential development of a public health crisis. Not yet recruiting --> Recruiting | Phase classification: P3 --> P4 | Trial completion date: Dec 2019 --> Mar 2022 | Trial primary completion date: Jun 2019 --> Sep 2021
- |||||||||| Targin (oxycodone/naloxone ER) / Shionogi, Purdue, Mundipharma
Clinical, Retrospective data, Journal: Laxative Use in Inpatients on Oxycodone/Naloxone Prolonged Release and Oxycodone Prolonged Release for Cancer and Non-cancer Pain. (Pubmed Central) - Sep 1, 2019
Not yet recruiting --> Recruiting | Phase classification: P3 --> P4 | Trial completion date: Dec 2019 --> Mar 2022 | Trial primary completion date: Jun 2019 --> Sep 2021 This retrospective study of hospital inpatients with cancer and non-cancer pain found that laxative use was not reduced in those on combined oxycodone/naloxone compared to oxycodone alone, suggesting that despite the interpretations of the clinical trials in the phase IV setting, the addition of naloxone had no effect on reducing laxative use.
- |||||||||| Herceptin (trastuzumab) / Roche
Journal: A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy. (Pubmed Central) - Jun 9, 2019
...Especially, the antibody Herceptin was modified onto the surface of nanoplatform for active HER2-targing to facilitate the tumor accumulation of the nanoplatform...The NIR-induced thermal effect subsequently triggered the optical droplet vaporization (ODV) of perfluorohexane (PFH) to generate PFH gas bubbles, which not only achieved the US imaging enhancement, but also contributed to the release of loaded paclitaxel (PTX) from the nanoplatform for significantly improving PTT therapeutic efficacy...The biocompatible PFH-PTX@PLGA/SPIO-Her nanoplatform as both photoacoustic/ultrasound bimodal imaging agents, photothermal-conversion nanomaterials (photothermal hyperthermia) and controllable drug delivery nanoagents (optical droplet vaporization) have completely eradicated the tumor without severe side effects. The theranostic strategy not only integrates strengthens of traditional imaging or therapeutic modalities, but also paves a new way for the efficient cancer treatment by taking the advantage of quickly-developing nanomedicine.
- |||||||||| oliceridine (TRV130) / Trevena, cebranopadol (GRT6005) / Assertio, Grunenthal, Targin (oxycodone/naloxone ER) / Shionogi, Purdue, Mundipharma
Review, Journal: Hot topics in opioid pharmacology: mixed and biased opioids. (Pubmed Central) - Jun 5, 2019
Moreover, the observation that β-arrestin coupling underlies the side-effect profile for MOP ligands (from knockout animal studies) led to the discovery of biased (to G-protein and away from β-arrestin intracellular signalling) MOP ligands, such as oliceridine. There is sufficient excitement in the opioid field to suggest that opioid analgesics without significant side-effects may be on the horizon, and the 'opioid Holy Grail' might be in reach.
- |||||||||| Targin (oxycodone/naloxone) / Shionogi, Purdue, Mundipharma
Clinical, Journal: Can early oral prolonged-release oxycodone, with or without naloxone reduce the duration of epidural analgesia after cystectomy? A three-arm, randomized, double-blind, placebo-controlled trial. (Pubmed Central) - Apr 3, 2019
Oxycodone, with or without naloxone, did not reduce the duration of TEA. Oxycodone alone led to a delayed return of bowel function, whereas the combination was not different from placebo.
|
